| Literature DB >> 35279111 |
Zuhui Zhang1,2, Yana Fu1,2, Jiajun Wang1, Xinpei Ji1, Zhangliang Li1,2, Yinying Zhao1,2, Pingjun Chang1,2, Yun-E Zhao3,4,5.
Abstract
BACKGROUND: This study aimed to identify the incidence of and risk factors for postoperative glaucoma-related adverse events at various time points after congenital cataract surgery.Entities:
Keywords: Congenital cataract surgery; Glaucoma-related adverse events; Incidence; Risk factors
Mesh:
Year: 2022 PMID: 35279111 PMCID: PMC8918280 DOI: 10.1186/s12886-022-02343-9
Source DB: PubMed Journal: BMC Ophthalmol ISSN: 1471-2415 Impact factor: 2.209
Clinical characteristics of patients with different surgical procedures
| Eyes, n | 111 | 85 | 63 | ||||||
| Right eye, n | 57 | 43 | 34 | ||||||
| Unilateral cataract, n (%) | 61 (55.0) | 22 (25.9) | 7(11.1) | < 0.001 | < 0.001 | 0.025 | |||
| IOL implantation, n | |||||||||
| In-the-bag | 109 | 68 | – | ||||||
| Sulcus | 2 | 17 | – | ||||||
| History of prematurity, n (%) | 7 (6.3) | 13 (15.3) | 4 (6.4) | 0.039 | 1.000 | 0.092 | 0.287 | 0.518 | 0.175 |
| FHCC, n (%) | 7 (6.3) | 12 (14.1) | 8 (12.7) | 0.067 | 0.149 | 0.803 | 0.525 | 0.838 | 0.621 |
| PFV, n (%) | 16 (14.4) | 17(20.0) | 10(15.9) | 0.300 | 0.795 | 0.520 | 0.015 | 0.037 | 0.566 |
| Age at surgery (months), Median (IQR) | |||||||||
| Primary surgery | 34.0 (15.0–46.0) | 4.0 (3.0–5.0) | 3.0 (2.0–4.0) | < 0.001 | < 0.001 | 0.008 | < 0.001 | < 0.001 | 0.045 |
| Secondary surgery | – | 34.0 (24.0–37.0) | – | ||||||
| Follow-up (months), Median (IQR) | 39.0 (29.0–53.0) | 50.0 (44.0–62.0) | 35.0 (27.0–44.0) | < 0.001 | 0.050 | < 0.001 | < 0.001 | 0.030 | < 0.001 |
| IOP (mmHg), Mean ± SD | |||||||||
| Baseline 1 | 12.9 ± 3.1 | 12.4 ± 2.6 | 10.8 ± 2.7 | 0.176 | < 0.001 | < 0.001 | 0.292 | < 0.001 | 0.002 |
| Baseline 2 | – | 13.9 ± 2.7 | – | ||||||
| Latest follow-up | 14.6 ± 3.1 | 16.8 ± 4.0 | 14.4 ± 3.1 | < 0.001 | 0.635 | < 0.001 | 0.001 | 0.503 | < 0.001 |
| Pre-op HCD (mm), Mean ± SD | 10.4 ± 0.6 | 9.4 ± 0.7 | 9.4 ± 1.0 | < 0.001 | < 0.001 | 0.982 | < 0.001 | < 0.001 | 0.903 |
| Pre-op CCT (μm), Mean ± SD | 541.1 ± 44.5 | 564.8 ± 49.7 | 574.6 ± 46.9 | 0.001 | < 0.001 | 0.230 | 0.012 | 0.002 | 0.359 |
| Pre-op ACD (mm), Mean ± SD | 2.9 ± 0.6 | 2.3 ± 0.4 | 2.4 ± 0.5 | < 0.001 | < 0.001 | 0.782 | < 0.001 | < 0.001 | 0.874 |
| Pre-op LT (mm), Mean ± SD | 3.7 ± 0.9 | 3.4 ± 1.0 | 3.1 ± 1.1 | 0.185 | 0.003 | 0.095 | 0.337 | 0.070 | 0.218 |
| Pre-op AL (mm), Mean ± SD | 21.5 ± 2.0 | 18.7 ± 1.1 | 17.9 ± 1.5 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | 0.006 |
| Glaucoma, n (%) | 0 (0) | 6 (7.1) | 4 (6.3) | 0.006 | 0.016 | 1.000 | 0.025 | 0.144 | 0.894 |
| Glaucoma suspect, n (%) | 0 (0) | 10 (11.8) | 1 (1.6) | < 0.001 | 0.362 | 0.025 | 0.010 | 0.304 | 0.058 |
| Glaucoma-related adverse events, n (%) | 0 (0) | 16 (18.8) | 5 (7.9) | < 0.001 | 0.006 | 0.061 | < 0.001 | 0.070 | 0.127 |
| Steroid-induced ocular hypertension, n (%) | 5 (4.5) | 17 (20.0) | 5 (7.9) | 0.001 | 0.499 | 0.041 | 0.009 | 0.211 | 0.038 |
P-value 1: Group 1 vs Group 2; P-value 2: Group 1 vs Group 3; P-value 3: Group 2 vs Group 3
* P values adjusted for unilateral cataract difference by generalised estimating equation
Baseline 1, primary preoperative IOP; Baseline 2, secondary preoperative IOP
IOL Intraocular lens, FHCC Family history of congenital cataract, PFV Persistent fetal vasculature, IQR Interquartile range, IOP Intraocular pressure, Pre-op Preoperative, HCD Horizontal corneal diameter, CCT Central corneal thickness, ACD Anterior chamber depth, LT Lens thickness, AL Axial length
Percentage of glaucoma, glaucoma suspect, and glaucoma-related adverse events
| 0 (0) | 1.2 (3) | 1.2 (3) | 1.2 (3) | 2.7 (6) | 3.8 (6) | |
| 0 (0) | 0 (0) | 0 (0) | 0.4 (1) | 1.3 (3) | 5.1 (8) | |
| 0 (0) | 1.2 (3) | 1.2 (3) | 1.6 (4) | 4.0 (9) | 8.9 (14) |
1 month, 6 months, and 1 year: number of eyes, N = 259; 2 years: number of eyes, N = 257; 3 years: number of eyes, N = 225; 4 years: number of eyes, N = 158
Fig. 1Cox proportional hazards regression analysis illustrating the cumulative probability of glaucoma-related adverse events
Clinical findings of glaucoma-related adverse events eyes after congenital cataract surgery patient
| Patient | Group | Sex | Eye | Glaucoma type | Age at primary surgery (months) | Age at secondary surgery (months) | IOL implantation | Age at glaucoma diagnosis (months) | IOP max (mmHg) | Anti-glaucoma |
|---|---|---|---|---|---|---|---|---|---|---|
| 2 | Female | Right | OAG | 7 | 35 | Sulcus | 29 | 30 | Topical antiglaucoma medications | |
| 2 | Female | Left | OAG | 7 | 35 | Sulcus | 29 | 31 | Topical antiglaucoma medications | |
| 3 | Male | Right | OAG | 2 | - | - | 58 | 30 | Topical antiglaucoma medications | |
| 3 | Male | Left | OAG | 2 | - | - | 58 | 27 | Topical antiglaucoma medications | |
| 2 | Male | Left | OAG | 1 | 17 | Sulcus | 62 | 28 | Topical antiglaucoma medications | |
| 2 | Male | Right | OAG | 5 | 39 | Sulcus | 54 | 35 | Topical antiglaucoma medications | |
| 2 | Female | Left | OAG | 8 | 22 | Sulcus | 25 | 28 | Topical antiglaucoma medications | |
| 2 | Female | Right | ACG | 2 | 27 | Sulcus | 6 | 43 | Anti-glaucoma surgery | |
| 3 | Male | Right | ACG | 1 | - | - | 3 | 31 | Anti-glaucoma surgery | |
| 3 | Male | Left | ACG | 1 | - | - | 6 | 27 | Anti-glaucoma surgery | |
| 2 | Female | Right | Glaucoma suspect | 7 | 35 | Sulcus | 50 | 28 | Topical antiglaucoma medications | |
| 2 | Female | Left | Glaucoma suspect | 7 | 35 | Sulcus | 50 | 28 | Topical antiglaucoma medications | |
| 2 | Female | Left | Glaucoma suspect | 4 | 24 | In-the-bag | 21 | 23 | Topical antiglaucoma medications | |
| 2 | Male | Right | Glaucoma suspect | 2 | 38 | In-the-bag | 35 | 30 | Topical antiglaucoma medications | |
| 2 | Male | Left | Glaucoma suspect | 2 | 38 | In-the-bag | 35 | 31 | Topical antiglaucoma medications | |
| 2 | Male | Right | Glaucoma suspect | 6 | 31 | Sulcus | 41 | 31 | Topical antiglaucoma medications | |
| 2 | Male | Left | Glaucoma suspect | 6 | 31 | In-the-bag | 41 | 32 | Topical antiglaucoma medications | |
| 3 | Female | Right | Glaucoma suspect | 2 | - | - | 41 | 35 | Topical antiglaucoma medications | |
| 2 | Male | Right | Glaucoma suspect | 3 | 35 | In-the-bag | 52 | 27 | Topical antiglaucoma medications | |
| 2 | Male | Right | Glaucoma suspect | 2 | 43 | In-the-bag | 47 | 30 | Topical antiglaucoma medications | |
| 2 | Male | Left | Glaucoma suspect | 2 | 43 | Sulcus | 47 | 31 | Topical antiglaucoma medications |
IOL Intraocular lens, IOP max Highest intraocular pressure measured, OAG Open-angle glaucoma, ACG Angle-closure glaucoma
Univariate and multivariable Cox regression analysis of risk factors for glaucoma-related adverse events in the group 2 and 3
| Potential risk factors | Univariate analysis | Multivariable analysis | ||
|---|---|---|---|---|
| 0.803 (0.332–1.941) | 0.626 | |||
| 0.979 (0.801–1.195) | 0.833 | |||
| 4.461 (1.763–11.285) | 0.002 | 50.463 (7.051–361.139) | < 0.001 | |
| 1.494 (0.493–4.521) | 0.478 | |||
| 1.489 (0.543–4.081) | 0.439 | |||
| 0.678 (0.479–0.959) | 0.028 | 1.325 (0.750–2.341) | 0.332 | |
| 1.013 (1.005–1.021) | 0.002 | 1.021 (1.009–1.034) | 0.001 | |
| 4.049 (2.105–7.752) | < 0.001 | 3.922 (1.558–9.804) | 0.004 | |
| 0.126 (0.021–0.755) | 0.023 | 0.256 (0.020–3.357) | 0.300 | |
| 3.559 (1.656–7.634) | 0.001 | 3.745 (1.344–10.417) | 0.012 | |
| 0.921 (0.321–2.641) | 0.879 | |||
HR Hazard ratio, CI Confidence intervals, FHCC Family history of congenital cataract, PFV Persistent fetal vasculature, Pre-op Preoperative, AL Axial length, CCT Central corneal thickness, HCD Horizontal corneal diameter, ACD Anterior chamber depth, LT Lens thickness, IOL Intraocular lens